BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 30652303)

  • 1. AZD8835 inhibits osteoclastogenesis and periodontitis-induced alveolar bone loss in rats.
    Wang Y; Chen X; Chen X; Zhou Z; Xu W; Xu F; Zhang S
    J Cell Physiol; 2019 Jul; 234(7):10432-10444. PubMed ID: 30652303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-κB Pathways In Vitro and Alveolar Bone Loss In Vivo.
    Ihn HJ; Kim YS; Lim S; Bae JS; Jung JC; Kim YH; Park JW; Wang Z; Koh JT; Bae YC; Baek MC; Park EK
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
    Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
    Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palmitoleic Acid Inhibits RANKL-Induced Osteoclastogenesis and Bone Resorption by Suppressing NF-κB and MAPK Signalling Pathways.
    van Heerden B; Kasonga A; Kruger MC; Coetzee M
    Nutrients; 2017 Apr; 9(5):. PubMed ID: 28452958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis induced by Aggregatibacter actinomycetemcomitans.
    Yu H; Herbert BA; Valerio M; Yarborough L; Hsu LC; Argraves KM
    Lipids Health Dis; 2015 Jul; 14():66. PubMed ID: 26138336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isobavachin attenuates osteoclastogenesis and periodontitis-induced bone loss by inhibiting cellular iron accumulation and mitochondrial biogenesis.
    Li T; Du Y; Yao H; Zhao B; Wang Z; Chen R; Ji Y; Du M
    Biochem Pharmacol; 2024 Jun; 224():116202. PubMed ID: 38615917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-21 promotes osteoclastogenesis in RAW264.7 cells through the PI3K/AKT signaling pathway independently of RANKL.
    Xing R; Zhang Y; Li C; Sun L; Yang L; Zhao J; Liu X
    Int J Mol Med; 2016 Oct; 38(4):1125-34. PubMed ID: 27599586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoxin A4 suppresses osteoclastogenesis in RAW264.7 cells and prevents ovariectomy-induced bone loss.
    Liu C; Guan H; Cai C; Li F; Xiao J
    Exp Cell Res; 2017 Mar; 352(2):293-303. PubMed ID: 28209487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation.
    Shim KS; Ma CJ; Kim DS; Ma JY
    J Med Food; 2011 Nov; 14(11):1439-47. PubMed ID: 21883017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Garcinol suppresses RANKL-induced osteoclastogenesis and its underlying mechanism.
    Jia Y; Jiang J; Lu X; Zhang T; Zhao K; Han W; Yang W; Qian Y
    J Cell Physiol; 2019 May; 234(5):7498-7509. PubMed ID: 30471112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
    Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
    Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anethole inhibits RANKL-induced osteoclastogenesis by downregulating ERK/AKT signaling and prevents ovariectomy-induced bone loss in vivo.
    Qu H; Zhang Y; He R; Lin N; Wang C
    Int Immunopharmacol; 2021 Nov; 100():108113. PubMed ID: 34530203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
    Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
    Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OCLI-023, a Novel Pyrimidine Compound, Suppresses Osteoclastogenesis In Vitro and Alveolar Bone Resorption In Vivo.
    Ihn HJ; Lee T; Kim JA; Lee D; Kim ND; Shin HI; Bae YC; Park EK
    PLoS One; 2017; 12(1):e0170159. PubMed ID: 28085946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nirogacestat suppresses RANKL-Induced osteoclast formation in vitro and attenuates LPS-Induced bone resorption in vivo.
    Chen X; Chen X; Zhou Z; Mao Y; Wang Y; Ma Z; Xu W; Qin A; Zhang S
    Exp Cell Res; 2019 Sep; 382(1):111470. PubMed ID: 31211955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
    Song J; Jing Z; Hu W; Yu J; Cui X
    Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncaria tomentosa reduces osteoclastic bone loss in vivo.
    Lima V; Melo IM; Taira TM; Buitrago LYW; Fonteles CSR; Leal LKAM; Souza ASQ; Almeida TS; Costa Filho RND; Moraes MO; Cunha FQ; Fukada SY
    Phytomedicine; 2020 Dec; 79():153327. PubMed ID: 32920290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.